Enliven Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(89,024) | $(71,584) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 317 | 297 |
| Stock-based compensation | 20,174 | 12,914 |
| Non-cash lease expense | 320 | 306 |
| Amortization of premiums and discounts on marketable securities, net | 424 | (4,603) |
| Change in fair value of contingent value right liability | (873) | — |
| Loss on disposal of property and equipment | 11 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and long-term assets | (4,768) | (3,703) |
| Operating lease liabilities | (335) | (310) |
| Accounts payable | 810 | (2,250) |
| Accrued expenses and other liabilities | (248) | 7,664 |
| Net cash used in operating activities | (73,192) | (61,269) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 313,914 | 120,000 |
| Purchases of marketable securities | (350,740) | (268,263) |
| Receipt of contingent value right milestone | 10,000 | — |
| Payment of contingent value right milestone, net of permitted deductions | (9,127) | — |
| Purchases of property and equipment | (44) | (149) |
| Net cash used in investing activities | (35,997) | (148,412) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 3,631 | 399 |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 651 | — |
| Proceeds from issuance of common stock and Pre-Funded Warrants in the Private Placement, net of issuance costs | 89,695 | — |
| Proceeds from issuance of common stock under the Sales Agreement, net of issuance costs | 39,188 | — |
| Payment of deferred offering costs related to the establishment of the Sales Agreement | — | (563) |
| Proceeds from the Financing Transaction, net of issuance costs | — | 161,365 |
| Cash acquired in connection with the reverse recapitalization | — | 81,821 |
| Payment of reverse recapitalization transaction costs | — | (8,736) |
| Net cash provided by financing activities | 133,165 | 234,286 |
| Net increase in cash, cash equivalents and restricted cash | 23,976 | 24,605 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 100,195 | 75,590 |
| Cash, cash equivalents and restricted cash at the end of the period | $124,171 | $100,195 |
| Components of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $124,117 | $100,141 |
| Restricted cash | 54 | 54 |
| Total cash, cash equivalents and restricted cash | $124,171 | $100,195 |
| Supplemental disclosure of cash flow information: | ||
| Income taxes paid related to the contingent value right milestone | $232 | $— |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock to common stock | $— | $149,749 |
| Receivables from stock option exercises included in prepaid expenses and other current assets | $— | $76 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.